CoChat

Subtype-Selective GABAA Receptor Modulation Yields a Novel Pharmacological Profile: The Design and Development of TPA023

Atack, John R. · 2009 · Advances in Pharmacology

The DOI matches its Crossref record; 110 of the 111 references it cites were found in a registry or an index.

Abstract

TPA023 is a GABA(A) alpha2/alpha3 subtype-selective modulator which in preclinical species has anxiolytic-like activity but does not produce sedative-like properties and is without abuse potential. It has good oral bioavailability in rat and dog but not in rhesus monkey (respective oral bioavailability values of 36, 54, and 1%), and in all the three species the half-life after i.v. administration was relatively short (0.6-1.5 h). The plasma concentrations of TPA023 required to produce 50% receptor occupancy were 21-25, 19, and 9 ng/mL in rats, baboons, and humans, respectively. In man, TPA023 has a half-life of around 3-6h when administered as an immediate release formulation, but exposure was more prolonged when it was formulated into a controlled release, gel extrusion module (GEM) tablet. In vivo metabolism was via t-butyl hydroxylation and N-deethylation. A drug-drug interaction study with itraconazole confirmed in vitro metabolic results implicating CYP3A enzymes as the major contributors to in vivo oxidative metabolism. The maximum tolerated doses in healthy, normal volunteers were 2 and 8mg for the immediate-release and GEM formulations, respectively. A post hoc analysis of three separate Phase IIa studies, all of which were halted prematurely, showed that TPA023 reduced scores on the Hamilton Anxiety Scale to a significantly greater extent than placebo. In addition, TPA023 has recently been reported to produce a trend toward improved cognitive performance in a small group of schizophrenia patients. Collectively, these data demonstrate that the alpha2/alpha3-selective partial agonist efficacy of TPA023 translates into a novel pharmacological profile.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1054-3589(08)57004-9

Cites

110 of 110 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 110 references

Research works printed but not linked: 6

  1. 2007, NME digest, Drug News & Perspectives, 20, 635
  2. 2008, Psychopharmacologic drugs, Drug Data Report, 30, 482
  3. Atack, 2009, GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics, Current Topics in Medicinal Chemistry
  4. Atack, 2009, MRK-409, a GABAA receptor subtype-selective agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in man, Journal of Psychopharmacology
  5. Fischer, 2009, Evaluation of the role of GABAA receptors containing α3 subunits in the therapeutic and unwanted side effects of benzodiazepine-type drugs in monkeys
  6. Volz, 2007, Benzodiazepines for schizophrenia (Review), Cochrane Database of Systematic Reviews, 1, CD006391

Cited by

See all 56

Metadata

Authors
Atack, J. R.
Affiliations
Janssen Research & Development (United States) (US)
Corresponding author
Atack, John R.
Venue
Advances in Pharmacology
Publisher
Elsevier
Published
2009
Volume
57
Pages
137-185
ISSN
1054-3589 (ISSN-L)
OpenAlex
W1520508152
Cited by
52
References
111
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 3 · 2017: 4 · 2016: 2 · 2014: 5 · 2013: 3 · 2012: 6
FWCI
5.57
Type
book chapter
Language
en
Open access
closed
Locations
  • Advances in pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
GABAA receptor, anxiolytic effects, abuse liability, oral bioavailability, pharmacokinetics, drug-drug interactions, CYP3A metabolism, itraconazole, controlled-release formulation, maximum tolerated dose, schizophrenia, cognitive performance, Hamilton Anxiety Rating Scale
MeSH terms
Amino Acid Sequence, Animals, Anxiety, Drug Evaluation, Preclinical, Humans, Molecular Sequence Data, Pyridazines, Receptors, GABA-A, Triazoles, Drug Design, Protein Subunits

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Subtype-Selective GABAA Receptor Modulation Yields a Novel Pharmacological Profile: The Design and Development of TPA023. https://app.cochat.ai/papers/10.1016/s1054-3589(08)57004-9
The paper
Atack, J. R. (2009). Subtype-Selective GABAA Receptor Modulation Yields a Novel Pharmacological Profile: The Design and Development of TPA023. Advances in Pharmacology. https://doi.org/10.1016/s1054-3589(08)57004-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.